BRIEF-Innovent Announces Strategic Collaboration With Lilly To Develop New Medicines Globally In Oncology And Immunology

Eli Lilly and Company -1.89% Post

Eli Lilly and Company

LLY

905.03

905.27

-1.89%

+0.03% Post

Feb 8 (Reuters) - Innovent Biologics Inc 1801.HK:

  • INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY

  • INNOVENT BIOLOGICS - INNOVENT WILL RECEIVE A $350 MILLION UPFRONT PAYMENT

  • INNOVENT BIOLOGICS: IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY & COMMERCIAL MILESTONE PAYMENTS UP TO EST $8.5 BILLION CONTINGEN CERTAIN FUTURE EVENTS

  • : INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY

Source text: ID:nPn5mzt1ta

Further company coverage: [1801.HK LLY.N]


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.